UNSPSC 51322401: Avasimibe

This classification denotes an anti-lipidemic agent with the molecular formula C29H43NO4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 28LQ20T5RC, chemically known as 2,6-diisopropylphenyl ((2,4,6-triisopropylphenyl)acetyl)sulfamate but generally known as avasimibe, which bears US NIH Compound Identifier 166558. European Medicines Agency schedules Avasimibe in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00632MIG.

UNSPSC 51322401 Avasimibe, a Commodity code, encompasses prescription and over-the-counter pharmaceutical products procured by state and local health systems, emergency services, and pharmacy benefit programs. State and local governments buy specific pharmaceutical formulations under this code — individual medication line items identified by National Drug Code (NDC), strength, dosage form, and unit quantity — for distribution through authorized wholesalers, direct dispensing by fire rescue and emergency medical services, and state employee and Medicaid pharmacy programs. Issuing bodies include city purchasing departments (Tampa), state health and human services commissions (Texas HHS), and state-administered cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance). These entities acquire both branded and generic medications, with procurement mechanisms ranging from competitive sealed bids for immediate supply needs to RFPs and RFIs for long-term statewide or multistate programs.

Recent activity spans the South, Southwest, and Upper Midwest. The City of Tampa's Purchasing Department posted an IFB (26P00188) on April 24, 2026, for Advanced Life Support Medications to supply Tampa Fire Rescue with epinephrine, labetalol, adenosine, and diltiazem vials, with a response deadline of April 8, 2026, and an estimated contract value of $40,000.00; the contract includes a Small Local Business Enterprise sheltered-market 5 percent bid discount and OSHA Safety Data Sheets compliance requirements. The Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, exploring direct contracting models outside traditional pharmacy benefit manager and wholesaler channels. The Minnesota Department of Administration, administering MMCAP, solicited an RFP (S1070000015802) posted January 20, 2026, with a response deadline of March 26, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, effective July 1, 2026; proposals require detailed NDC codes, SKU and UPC data, manufacturing locations, and compliance with cGMP and Drug Supply Chain Security Act standards.